Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03263494 · ClinicalTrials.gov registry record · Phase 3

CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)

A Phase 3 study, sponsored by Jaeb Center for Health Research.

Completed
Registry status
Phase 3
Development phase
153
Enrollment target

NCT03263494 is a Phase 3 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 153 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03263494, a Phase 3 study, has completed, sponsored by Jaeb Center for Health Research.

COMPLETED
Registry status
Phase 3
Development phase
153 participants
Enrollment target

Study Summary

Adolescents and young adults with T1D and poor glycemic control (age 14-\< 25 years, T1D duration \>12 months, HbA1c 7.5-\<11.0%, using an insulin pump or MDI)) will be randomly assigned to either CGM or BGM. Sample size will be 150. The primary outcome assessment will be HbA1c after 6 months. Secondary outcomes will include HbA1c, CGM metrics (control group will wear blinded CGM at 13 and 24 weeks), and quality of life measures. The randomized trial will be followed by a 6-month extension study during which the RCT control group will initiate CGM and the RCT CGM group will continue CGM.

Interventions

  • DEVICE Continuous Glucose Monitor (CGM)

Trial Details

FieldValue
Enrollment Target 153 participants
Start Date 2018-01-25
Est. Completion 2019-11-07
Phase Phase 3

Sponsor

Jaeb Center for Health Research

119 total trials

What the Registry Record Tells You About NCT03263494

The ClinicalTrials.gov registry entry for NCT03263494 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Continuous Glucose Monitor (CGM) is the first listed.

NCT03263494 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03263494 about?

NCT03263494 is a clinical study titled "CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)". Adolescents and young adults with T1D and poor glycemic control (age 14-\< 25 years, T1D duration \>12 months, HbA1c 7.5-\<11.0%, using an insulin pump or MDI)) will be randomly assigned to either CGM or BGM. Sample size will be 150. The primary outcome assessment will be HbA1c after 6 months. Secon...

What is the current status of trial NCT03263494?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2018-01-25. Estimated completion is 2019-11-07.

What interventions are being tested in trial NCT03263494?

The interventions under investigation include: Continuous Glucose Monitor (CGM) (DEVICE).

Who is sponsoring clinical trial NCT03263494?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.